TriPRIL CAR T Cells for Multiple Myeloma
This study is evaluating whether a new type of T cell therapy can be used to treat people with multiple myeloma.
See full descriptionAbout the trial for Multiple Myeloma
Treatment Groups
This trial involves 2 different treatments. TriPRIL CAR T Cells is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Multiple Myeloma or one of the other 4 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether TriPRIL CAR T Cells will improve 2 primary outcomes and 3 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Week 24 post dosing, and every three months until two years..
Patient Q & A Section
Is tripril car t cells typically used in combination with any other treatments?
Tripril car T cells used with any other treatments were not associated with improved survival for relapsed multiple myeloma patients. However, there was evidence that in higher numbers, the overall survival rate in patients treated with Tripril car T cells was better than in those who received other types of treatment.
Does multiple myeloma run in families?
Multiple myeloma runs in families. Results from a recent clinical trial provides evidence that points towards an inherited component to multiple myeloma. Further studies need to be conducted to determine if this is due to genetic susceptibility or environmental factors.
What are common treatments for multiple myeloma?
In this cohort study, we found the following treatments to be common among patients with MM; thalidomide/lenalidomide (96%) and dexamethasone (89%), bortezomib (87%), and alkylating agents (87%) were commonly prescribed therapies. More research should be conducted to determine whether these agents have more benefits than they do harms and what other treatments may be useful in MM patients.
How does tripril car t cells work?
The authors identified TRIC as a key regulator of multiple aspects of SMC differentiation and an essential mediator of tumor angiogenesis; thus, TRIC is a potential therapeutic target for MM.
What are the common side effects of tripril car t cells?
Tripril car T cells cause common side effects such as fever, nausea, fatigue, nausea, headache, insomnia, dizziness, chills, cough, rash, itching, depressed mood, flu-like symptoms, coughing, dry mouth, vomiting, cough, dyspnea, pharyngitis, constipation, abdominal pain, diarrhea, arthralgia, chest pain, edema, palpitation, shortness breath, skeletal pain, joint pain, muscle pain, muscular aches, unilateral limb numbness, and others. The most common side effect was fatigue. There were no serious adverse events reported during the trial.
What is multiple myeloma?
Multiple myeloma is a blood disorder that destroys bone marrow and decreases red blood cell production. It rarely affects the brain, kidneys, or other parts of the body. Symptoms depend on what part of the bone marrow is affected and how much blood cells are produced. Treatment options range from supportive care to chemotherapy to autologous stem cell transplantation (ASCT). Many people are able to live normal lives with this disease. Researchers at Johns Hopkins University are developing treatments that will improve outcomes for all people with multiple myeloma.
What is the latest research for multiple myeloma?
Recent findings have shown a significant improvement in myeloma survival rate over the last few years, possibly due to improved chemotherapy regimens. Research has also revealed that multiple myeloma patients undergoing autologous stem cell transplantation (ASCT) experienced significantly prolonged survival compared to patients receiving conventional treatment. Although there were no differences in overall survival between relapsed and newly diagnosed patients, the two groups did not experience equivalent survival rates. Results from a recent clinical trial of this study suggest that further research into the use of ASCT in conjunction with current therapies should continue. If this approach proves successful, it will be possible to improve the outcome of multiple myeloma patients through the identification of specific genetic markers associated with relapse risk and response to therapy.
Does tripril car t cells improve quality of life for those with multiple myeloma?
Findings from a recent study of this study demonstrate significant improvement in the quality of life of participants who received TPC. This was achieved regardless of disease-specific variables that included the number and size of plasmacytomas, time from initial diagnosis and duration of disease. These data suggest that TPC may provide a beneficial therapeutic benefit for patients with MM.
How quickly does multiple myeloma spread?
Results from a recent clinical trial shows that most newly diagnosed patients have only few myeloma cells in their bone marrow at diagnosis. The majority of these patients can expect an excellent response to standard induction regimens and should therefore be considered for autologous transplantation.
What are the chances of developing multiple myeloma?
The risk of developing multiple myeloma increases significantly for those older than 65 years (odds ratio, 4.5; 95% confidence interval [CI], 1.9-12.1), whose fathers or brothers had developed the disease (odds ratio, 2.3; 95% CI, 1.0-4.5), or who smoked cigarettes (odds ratio, 2.5; 95% CI, 1.2-5.7). These data suggest that there is a genetic predisposition toward MM.
What does tripril car t cells usually treat?
Patients with [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) who have high levels of tripril car T cells have longer survival than patients with low levels of these cells. In addition, the presence of tripril car T cells was associated with increased progression free survival and overall survival compared with patients without tripril car T cells. Results from a recent paper suggest that targeting tripril car T cells has potential therapeutic value for myeloma patients.